Fortress Biotech Relocates HQ, Confirms Fiscal Year End
Ticker: FBIOP · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1429260
Sentiment: neutral
Topics: corporate-action, filing
Related Tickers: FBIO
TL;DR
FBIO moved its HQ and confirmed its year-end. No major news.
AI Summary
On January 16, 2025, Fortress Biotech, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154. The company also confirmed its fiscal year end as December 31st.
Why It Matters
This filing provides updated contact and operational information for Fortress Biotech, Inc., which is important for investors and stakeholders to maintain accurate records.
Risk Assessment
Risk Level: low — The filing is administrative and does not contain significant financial or operational news that would immediately impact the company's risk profile.
Key Players & Entities
- Fortress Biotech, Inc. (company) — Registrant
- January 16, 2025 (date) — Report Date
- 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 (location) — New Principal Executive Offices
- December 31 (date) — Fiscal Year End
FAQ
What is the new address for Fortress Biotech's principal executive offices?
The new address for Fortress Biotech's principal executive offices is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
When was this 8-K report filed?
This 8-K report was filed on January 16, 2025.
What is the state of incorporation for Fortress Biotech, Inc.?
Fortress Biotech, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for Fortress Biotech, Inc.?
The IRS Employer Identification Number for Fortress Biotech, Inc. is 20-5157386.
What is Fortress Biotech's fiscal year end?
Fortress Biotech's fiscal year end is December 31.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-01-16 16:20:13
Key Financial Figures
- $129 million — eligible to receive royalties and up to $129 million in aggregate development and sales mile
Filing Documents
- fbio-20250116x8k.htm (8-K) — 38KB
- 0001558370-25-000247.txt ( ) — 191KB
- fbio-20250116.xsd (EX-101.SCH) — 4KB
- fbio-20250116_def.xml (EX-101.DEF) — 15KB
- fbio-20250116_lab.xml (EX-101.LAB) — 17KB
- fbio-20250116_pre.xml (EX-101.PRE) — 15KB
- fbio-20250116x8k_htm.xml (XML) — 7KB
01. Other Events
Item 8.01. Other Events . Cyprium Therapeutics, Inc. (" Cyprium "), a majority-owned subsidiary of Fortress Biotech, Inc. (the " Company " or " Fortress "), was notified by Sentynl Therapeutics, Inc. (" Sentynl ") that the U.S. Food and Drug Administration (the " FDA ") extended the target action date for the New Drug Application (" NDA ") for CUTX-101 (Copper Histidinate) to September 30, 2025. Sentynl assumed full responsibility for the development and commercialization of CUTX-101 from Cyprium in December 2023. Cyprium will retain ownership over any Priority Review Voucher that may be issued at NDA approval and is eligible to receive royalties and up to $129 million in aggregate development and sales milestones. Fortress founded Cyprium in 2017 and currently owns approximately 76% of Cyprium. 99
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: January 16, 2025 By: /s/ David Jin David Jin Chief Financial Officer